Medical Oncology

Uzm. Dr. Özde Melisa Celayir

Doctor and researcher Başakşehir Çam ve Sakura Şehir Hastanesi İstanbul
Breast NeoplasmsBreast Neoplasms, Male
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 4 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Breast Neoplasms, Male 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionBaşakşehir Çam ve Sakura Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 4 publications · Model version —From source
  • Publications24 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-8562-7085ORCIDFrom source
  • Last synchronised5 November 2026 10:37https://camsakurasehir.saglik.gov.tr/TR-1291063/gorev-yapan-hekimlerimiz.html#ozde-melisa-celayirsaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

24 publications

  1. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Open-access full textSource: OpenAlex

  2. Comparison of First-Line Pembrolizumab Monotherapy Versus Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Multicenter Real-World Study from Turkey

    Medicina, 2026

    DOI 10.3390/medicina62112136 Open-access full textSource: OpenAlex

  3. Real-World Outcomes of Fosaprepitant-Containing Prophylaxis in Patients Receiving Highly and Moderately Emetogenic Chemotherapy: A Two-Center Retrospective Study

    SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, 2026

    DOI 10.14744/semb.2026.32391 PMID 42824916 Open-access full textSource: OpenAlex

  4. Prognostic Value of the Lung Immune Prognostic Index in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: A Real-World Analysis Beyond PD-L1 Expression

    Diagnostics, 2026

    DOI 10.3390/diagnostics16182890 PMID 42793675 Open-access full textSource: ORCID

  5. Prognostic Value of the Lung Immune Prognostic Index in Advanced Non–Small Cell Lung Cancer Receiving Nivolumab: A Real-World Analysis Beyond PD-L1 Expression

    2026

    DOI 10.20944/preprints202605.1554.v1 Open-access full textSource: ORCID

  6. Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study

    Journal of Neuro-Oncology, 2026

    DOI 10.1007/s11060-025-05415-0 PMID 41492105 Source: OpenAlex

  7. BIOMARKERS AND PERSONALIZED MEDICINE IN OLDER CANCER PATIENTS

    Turkiye Klinikleri eBooks, 2026

    DOI 10.5336/978-625-91269-7-5_p117 Source: OpenAlex

  8. Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e20659 Source: OpenAlex

  9. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey

    Cancers, 2025

    DOI 10.3390/cancers17091592 PMID 40361516 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  10. The Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer: A Multicenter Real-World Study from Turkey

    2025

    DOI 10.20944/preprints202504.0284.v1 Open-access full textSource: ORCID

View all 24 publications